Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 19/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31277463 | 1.00 | ENPEP (0.46) | ENPEP | |
| SCHEMBL31318675 | 0.98 | ENPEP (0.47) | ENPEP | |
| SCHEMBL30111320 | 0.94 | NPY4R (0.43) | ENPEP | |
| SCHEMBL29379387 | 0.93 | ENPEP (0.43) | ENPEP | |
| SCHEMBL15011349 | 0.92 | NPY4R (0.40) | ENPEP | |
| SCHEMBL9614927 | 0.92 | NPY4R (0.40) | ENPEP | |
| SCHEMBL27732271 | 0.92 | NPY4R (0.40) | ENPEP | |
| SCHEMBL30456269 | 0.91 | NPY4R (0.48) | ENPEP | |
| SCHEMBL30456308 | 0.91 | NPY4R (0.48) | ENPEP | |
| SCHEMBL30148448 | 0.91 | NPY4R (0.48) | ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20240252586-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | ENPEP 26/4885 |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | IAPP, VIP, NGLY1 | ENPEP 16/4885 |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | ENPEP 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.